Sydney Jennings

Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.

The USPSTF's revised CRC screening guidelines to include adults aged 45-49 years increased screening needs by about 23% without additional funding or resources for CHCs.

Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.

Under risk-based guidelines, less than 30% of eligible adults are vaccinated against pneumococcal disease, said Robert Hopkins, Jr, MD. More details, here.

Your daily dose of the clinical news you may have missed.

Daily step counts of 5000 or more corresponded with fewer depressive symptoms, according to a recent systematic review and meta-analysis.

President of the Obesity Medicine Association discusses a recent joint statement from the OMA and 4 other organizations calling for inclusion of patients with obesity in drug research.

Your daily dose of the clinical news you may have missed.

The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.

Angela Fitch, MD, discusses the importance of clinician education in addressing obesity with patients.

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Your daily dose of the clinical news you may have missed.

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.

Your daily dose of the clinical news you may have missed.

A centralized mailed FIT outreach intervention significantly improved CRC screening in a diverse patient population, according to recent data

Your daily dose of the clinical news you may have missed.

New findings highlight the potential of this combination therapy as a new option for people with PTSD who have not responded to standard treatments.

Your daily dose of the clinical news you may have missed.

From ACIP updates on age eligibility and research on vaccine efficacy to US adults' attitudes toward recommended shots, these 10 at-a-glance news briefs are must-reads for PCPs.

Your daily dose of the clinical news you may have missed.

Nemolizumab is the first approved monoclonal antibody that targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.

Your daily dose of the clinical news you may have missed.

Intra-Cellular Therapies submitted an sNDA to the FDA for lumateperone for the treatment of MDD in adults as as adjunctive therapy to antidepressants.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The Prescription Drug User Fee Act date is set for May 7, 2025.

Your daily dose of the clinical news you may have missed.